Summary of Study ST002185

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001392. The data can be accessed directly via it's Project DOI: 10.21228/M8SH87 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)

Study ID	ST002185
Study Title	Lipidomic characterization of Jurkat-derived T cell line in which the chaperonin complex CCT has been partially silenced
Study Type	Untargeted Lipidomics
Study Summary	When the chaperonin complex CCT is partially silenced in Jurkat-derived T cell line J77 E61, we observe changes in the production of exosomes and in their composition. Thus, to explore the bases of these alterations and find possible new mechanisms of exosome biosynthesis regulation we characterized the lipidome content in cells where the chaperonin complex CCT was partially silent (CCT) and controls (CTRL). We analyzed 5 biological replicates containing 3 × 106 cells using LC-MS in positive and negative polarity mode. For quality control, 5 QCs samples and 4 blanks were also included in the analysis (total 19 samples and 2 groups).
Institute	Centro Nacional de Investigaciones Cardiovasculares Carlos III
Department	Proteomics and Metabolomics Unit
Laboratory	Metabolomics Lab
Last Name	Ferrarini
First Name	Alessia
Address	Calle de Melchor Fernández Almagro, 3, Madrid, Madrid, 28029, Spain
Email	aferrarini@cnic.es
Phone	914 53 12 00
Submit Date	2022-06-03
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2023-06-06
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002283
Treatment Summary:	E6-1 Jurkat cells were transfected with a pool of double-stranded siRNAs targeting CCT1 (5’-CCAUUGGAGACUUGGUAAA-3’), CCT2 (5’-UGGUAAACCUCGAGACAAC-3’), CCT4 (5’- AGGUGGUGCUCCAGAAAUA-3’) and CCT5 (5’-CCAGACAGGUGAAGGAGAU-3’). As control, cells were transfected with a nonspecific siRNA (5’-UUCUCCGAACGUGUGCACG-3’). Cells were resuspended in Opti-MEM (Gibco; 1 x 106 cells per ml) with 1.2 M of each siRNA to a total of 5 M and electroporated with Gene PulserXcell (Bio-Rad) at 240 mV and 95 mA in 4 mm cuvettes (Bio-Rad). Silencing was effective from 48 h until 72 h after the transfection step.

Treatment ID:

TR002283

Treatment Summary:

E6-1 Jurkat cells were transfected with a pool of double-stranded siRNAs targeting CCT1 (5’-CCAUUGGAGACUUGGUAAA-3’), CCT2 (5’-UGGUAAACCUCGAGACAAC-3’), CCT4 (5’- AGGUGGUGCUCCAGAAAUA-3’) and CCT5 (5’-CCAGACAGGUGAAGGAGAU-3’). As control, cells were transfected with a nonspecific siRNA (5’-UUCUCCGAACGUGUGCACG-3’). Cells were resuspended in Opti-MEM (Gibco; 1 x 106 cells per ml) with 1.2 M of each siRNA to a total of 5 M and electroporated with Gene PulserXcell (Bio-Rad) at 240 mV and 95 mA in 4 mm cuvettes (Bio-Rad). Silencing was effective from 48 h until 72 h after the transfection step.